NASDAQ:PODD - Insulet Stock Price, Forecast & News

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings data on Tuesday, November, 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.02. The medical instruments supplier had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. Insulet had a return on equity of 10.34% and a net margin of 2.38%. The firm's revenue was up 27.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.03 EPS. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insulet.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $841.548-871.076 million, compared to the consensus revenue estimate of $879.83 million.

17 brokerages have issued 12 month price targets for Insulet's shares. Their forecasts range from $100.00 to $213.00. On average, they expect Insulet's share price to reach $162.06 in the next year. This suggests that the stock has a possible downside of 17.6%. View Analyst Price Targets for Insulet.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Insulet.

News stories about PODD stock have been trending somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insulet earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Varian Medical Systems (VAR) and Hologic (HOLX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), DexCom (DXCM), Roku (ROKU), salesforce.com (CRM), Tandem Diabetes Care (TNDM), Adobe (ADBE), Splunk (SPLK) and Veeva Systems (VEEV).

Insulet's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (10.81%), Capital World Investors (6.47%), William Blair Investment Management LLC (2.59%), Fred Alger Management LLC (2.34%), Alliancebernstein L.P. (1.43%) and Geode Capital Management LLC (1.15%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CSS LLC IL, Capital Research Global Investors, Fred Alger Management LLC, Goldman Sachs Group Inc., Alliancebernstein L.P., Jennison Associates LLC, Eagle Asset Management Inc. and Russell Investments Group Ltd.. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Renaissance Technologies LLC, Beacon Investment Advisory Services Inc., Sumitomo Mitsui Trust Holdings Inc., Capital International Investors, UBS Asset Management Americas Inc., Swiss National Bank and SG Americas Securities LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $196.73.

Insulet has a market capitalization of $12.16 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]